| Filed On | Filing |
|---|---|
| 04 Nov 2026 |
8-K: Results of Operations and Financial Condition
- Third quarter GAAP total revenues of $342 million, up 22% year-over-year as compared to non-GAAP adjusted total revenues |
| 23 Oct 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
As previously disclosed in our Current Report on Form 8-K filed with the Securities and Exchange Commission on May 1, 2026, on April 27, 2026, Elizabeth H.Z. Thompson, Ph.D., Executive Vice President, Head of Research and Development of ... |
| 24 Sep 2026 |
8-K: Regulation FD Disclosure; Other Events
Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP) |
| 11 Sep 2026 |
8-K: Other Events
This Stipulation and Agreement of Settlement (the “Stipulation”) dated July 9, 2026, is entered into by and among the following Parties (defined herein) by and through their respective counsel: |
| 04 Aug 2026 |
8-K: Results of Operations and Financial Condition
- Second quarter DAYBUE® GAAP net sales of $125 million, up 30% year-over-year driven by strong uptake of DAYBUE STIX |
| 29 May 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
(a) Successor to and Continuation of Prior Plan. The Plan is the successor to and continuation of the Prior Plan. As of the Effective Date, (i) no additional awards could be granted under the Prior Plan or the 2023 Inducement Plan; (ii) ... |
| 06 May 2026 |
8-K: Results of Operations and Financial Condition
- First quarter DAYBUE® GAAP net sales of $101 million, up 20% year-over-year; Successful Launch of DAYBUE STIX Underway |
| 01 May 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
Acadia Pharmaceuticals Announces Planned Year-End Retirement of Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development, Following a Distinguished Career |
| 05 Mar 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On March 3, 2026, the board of directors (the “Board”) of Acadia Pharmaceuticals Inc. (the “Company”), upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Jonathan M. Poole to the Board to fil... |
| 25 Feb 2026 |
8-K: Results of Operations and Financial Condition
- Fourth quarter 2025 GAAP total revenues of $284 million and full year 2025 GAAP total revenues of $1.07 billion, reflecting 9% and 12% year over year growth respectively |
| 13 Jan 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
On January 13, 2026, Acadia Pharmaceuticals, Inc. (the “Company”) presented at the J.P. Morgan Healthcare Conference announcing, among other things, that it anticipates 2025 net sales will exceed $1 billion, consistent with prior guidanc... |
| 05 Nov 2025 |
8-K: Results of Operations and Financial Condition
- Third quarter total revenues of $278.6 million, up 11% year-over-year |
| 03 Nov 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
On October 28, 2025, Daniel B. Soland notified the Board of Directors (the “Board”) of Acadia Pharmaceuticals Inc. (the “Company”) of his resignation from the Board and from his positions as a member and Chair of the Nominating and Corpo... |
| 06 Aug 2025 |
8-K: Results of Operations and Financial Condition
- Second quarter total revenues of $264.6 million, up 9% year-over-year |
| 10 Jun 2025 |
8-K: Other Events
On June 9, 2025, Acadia Pharmaceuticals Inc. (the “Company”) announced that the U.S. Court of Appeals for the Federal Circuit (the “Court”) affirmed a decision issued by the U.S. District Court for the District of Delaware in the Company... |
| 29 May 2025 |
8-K: Submission of Matters to a Vote of Security Holders
(a) On May 29, 2025, Acadia Pharmaceuticals Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “2025 Annual Meeting”). |
| 20 May 2025 |
8-K: Entry into a Material Definitive Agreement; Other Events
On May 15, 2025, Acadia Pharmaceuticals Inc. (the “Company”) entered into a Lease and Lease Agreement (the “210 Lease”) with 210 Associates Limited Partnership (the “Landlord”) for the lease of approximately 52,771 rentable square feet o... |
| 07 May 2025 |
8-K: Results of Operations and Financial Condition
- First quarter total revenues of $244.3 million, up 19% year-over-year |
| 16 Apr 2025 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year
Section 1. Registered Office. The registered office of Acadia Pharmaceuticals Inc. (the “Corporation”) in the State of Delaware and the name of the Corporation’s registered agent at such address shall be as set forth in the certificate o... |
| 26 Feb 2025 |
8-K: Results of Operations and Financial Condition
- 2024 total net product sales of $957.8 million, reflecting 32% revenue growth |
Loading...